NewsNovo
About 36% of employers cover GLP-1 drugs for both diabetes and weight loss, matching last year's figure and up from 34% in 2024, according to a recent survey.
The two-point gain from 2024 looks, at first read, like forward motion.
The more recent comparison is the one worth holding: coverage did not move from 2025 into the current survey period, and many employers are finding ways around broader access rather than choosing to build it.
What the numbers say A gain from 34% to 36% is the kind of data point that gets packaged as a trend. The problem is it stopped there. Coverage held flat year over year, from 2025 to the current survey period, at 36%.
Keep reading